Amy Praestgaard, n/a

MS
Sanofi, Cambridge, MA, USA

Poster(s):

• (236) Dupilumab monotherapy vs topical corticosteroids in prurigo nodularis: impact on signs and symptoms in the PRIME/PRIME2 studies
  Wednesday, October 29, 2025